The Influence of Sitagliptin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Prespecified Sub-Analysis
暂无分享,去创建一个
I. Shimomura | H. Watada | H. Ishii | M. Gosho | T. Shiraiwa | N. Katakami | T. Mita | H. Yoshii
[1] 8. Pharmacologic Approaches to Glycemic Treatment , 2016, Diabetes Care.
[2] I. Shimomura,et al. Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE) , 2016, Diabetes Care.
[3] H. Itoh,et al. Efficacy and Safety of Sitagliptin Added to Insulin in Japanese Patients with Type 2 Diabetes: The EDIT Randomized Trial , 2015, PloS one.
[4] I. Shimomura,et al. Rationale, design, and baseline characteristics of a clinical trial for prevention of atherosclerosis in patients with insulin-treated type 2 diabetes mellitus using DPP-4 inhibitor: the Sitagliptin Preventive study of Intima-media thickness Evaluation (SPIKE) , 2014, Diabetology & Metabolic Syndrome.
[5] T. Kondo,et al. Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy. , 2013, Endocrine journal.
[6] M. Namba,et al. Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus. , 2013, Endocrine journal.
[7] J. Oyama,et al. Effects of sitagliptin beyond glycemic control: focus on quality of life , 2013, Cardiovascular Diabetology.
[8] H. Ishii. Development and Psychometric validation of the Diabetes Therapy-Related QOL (DTR-QOL) Questionnaire , 2012, Journal of medical economics.
[9] N. Tajima,et al. Efficacy of combined use of miglitol in Type 2 diabetes patients receiving insulin therapy-placebo-controlled double-blind comparative study , 2011, Acta Diabetologica.
[10] F. Camacho,et al. Diabetes Medication Satisfaction Tool , 2009, Diabetes Care.
[11] F. Camacho,et al. The Diabetes Medication Satisfaction Tool (DMSAT): A Focus on Treatment Regimens , 2008 .
[12] H. Ishii,et al. Improvement of glycemic control and quality-of-life by insulin lispro therapy: Assessing benefits by ITR-QOL questionnaires. , 2008, Diabetes research and clinical practice.
[13] B. Frier,et al. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? , 2008, Diabetes/metabolism research and reviews.
[14] B. Adams-Huet,et al. Weight gain in type 2 diabetes mellitus , 2007, Diabetes, obesity & metabolism.
[15] B. Goldstein,et al. Cardiovascular risk in the spectrum of type 2 diabetes mellitus. , 2006, The Mount Sinai journal of medicine, New York.
[16] T. Yoshikawa,et al. Efficacy of glimepiride in patients with poorly controlled insulin-treated type 2 diabetes mellitus. , 2005, Endocrine journal.
[17] H. Bilo,et al. Cross-sectional relationship between glycaemic control, hyperglycaemic symptoms and quality of life in type 2 diabetes (ZODIAC-2). , 2005, The Netherlands journal of medicine.
[18] P. Raskin,et al. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. , 2002, Diabetes care.
[19] Kenzo Oba,et al. [Treatment guide for diabetes]. , 2011, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics.
[20] J. Nunnally. Psychometric Theory (2nd ed), New York: McGraw-Hill. , 1978 .